EKF Diagnostics, the global in vitro diagnostics company, has acquired Advanced Diagnostic Laboratory (“ADL Health”), a Texas based PCR-focused testing laboratory certified under the Clinical Laboratory Improvement Amendments (“CLIA”) for high-complexity molecular diagnostics testing. ADL Health’s CLIA-certified laboratory covers the fields of clinical, forensic and microbiological tests. The business has ISO 15189 Medical Laboratory accreditation […]

AMSBIO has expanded its range of custom gene editing services to complement its extensive portfolio of off-the-shelf CRISPR/Cas9 products. AMSBIO CRISPR/Cas9 products are widely used by research groups worldwide in applications including gene mutation studies, epigenetic editing, cell and embryo therapies, and genomic-scale screening.

SciRhom GmbH, a therapeutic antibody developer, announced the addition of Dr. Jürgen Reeß to the management team as Chief Medical Officer. At the same time, the company is strengthening its business and scientific strategy with the establishment of a Board of Directors. The three members of the Board, Prof. Carl Blobel, Dr. Wolfgang Baiker, and Mr. Hans-Ulrich Rabe, will be instrumental in steering the company along a successful path through the next phase of its development. In January 2022, Dr. Andreas Jenne, currently Chief Business Officer of SciRhom, will move from management and join the Board of Directors as a fourth member.

SciRhom has taken critical steps in advancing their first-in-class antibodies against iRhom2 towards clinical development. Proof-of-principle studies demonstrated preclinical efficacy of the drug candidates in protecting mice against rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). The antibodies suppress iRhom2, thereby inhibiting tumour necrosis factor-alpha-convertase (TACE; also known as ADAM17), which conversely blocks several disease-causing signalling pathways. Achievement of this milestone also marks the beginning of the next stage in product development and company progress.

“SciRhom is an agile enterprise,” explained Chief Executive Officer Dr. Jens Ruhe. “As we move into this exciting new development phase, we’ve fine-tuned company structures to ensure that our ranks include top expertise to guarantee successful outcomes. We are in an extraordinary position to have such renowned and experienced partners join our efforts. Each member of our management team and our Board of Directors plays an indispensable role in swiftly moving our innovative therapy concept from our labs to patients with debilitating autoimmune diseases.”

Dr. Jürgen Reeß joins the corporate management team to guide the continued evolution of the therapeutic product and coordinate the company’s development pipelines focused on RA, IBD, and systemic lupus erythematosus glomerulonephritis. A trained physician with a medical and doctorate degree from the University of Ulm, Germany, Dr. Reeß has been a longstanding leader in the pharmaceutical industry. He has supervised the development, approval, and launch of numerous major therapies across several therapy areas, most recently as Corporate Senior Vice President of International Project Management at Boehringer Ingelheim Human Pharma.

The new Board of Directors will include SciRhom co-founder Prof. Carl Blobel, whose groundbreaking research laid the scientific foundation of SciRhom’s technology. Dr. Blobel is Professor of Medicine and of Physiology, Biophysics and Systems Biology at Weill Cornell Medicine, and Chairman of the Arthritis and Tissue Degeneration Program at the Hospital for Special Surgery in New York City. His in-depth knowledge of iRhom2 and TACE will guide the technological roadmap of the company and strengthen the scientific evolution of the product.

The second Board member, Dr. Wolfgang Baiker, is an internationally respected advisor and partner for multiple life science business projects. As Venture Partner at Wellington Partners Venture Fund, Dr. Baiker has leveraged his years-long experience as Board member and CEO of Boehringer Ingelheim USA to help rising companies establish themselves in an international market. He is also an investor in SciRhom. Dr. Baiker fulfils a key role in shaping the corporate strategy to grow SciRhom’s organization and infrastructure.

Hans-Ulrich Rabe rounds off the new Board of Directors. A trusted advisor in strategic asset allocation and direct investment in high-potential biotech companies, Mr. Rabe represents a consortium of four private investors – SciRhom’s largest investment group. With strong business acumen and extensive experience in mentoring companies and fostering their development, Mr. Rabe brings a wealth of expertise in logistics, risk assessment, and finance management to fortify the company’s performance.

Having successfully secured seed funding for SciRhom as the Chief Business Officer, Dr. Andreas Jenne will move from corporate management to the Board of Directors in January 2022. A co-founder of SciRhom, Dr. Jenne has comprehensive knowledge of the company. His appointment to the Board of Directors aligns with the transition of SciRhom from start-up to product-oriented enterprise.

Researchers at Karolinska Institutet in Sweden report that a recently discovered inflammatory mediator, interleukin-26, appears to have an important role in pneumonia and contribute to the killing of bacteria. The study is published in the scientific journal Frontiers in Immunology – Microbial Immunology.

AMSBIO report that researchers from the Medical University of Vienna, have used Lipidure – CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.